Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00379470 · ClinicalTrials.gov registry record · Phase 3

Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)

A Phase 3 study of Recurrent Glioblastoma Multiforme, sponsored by NovoCure.

Completed
Registry status
Phase 3
Development phase
236
Enrollment target
20
Study locations

NCT00379470 is a Phase 3 study of Recurrent Glioblastoma Multiforme that has completed, run by NovoCure. The registered enrollment target is 236 participants, above the 64-participant average among 6 other Recurrent Glioblastoma Multiforme trials with a reported enrollment target (269% higher). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00379470, a Phase 3 study of Recurrent Glioblastoma Multiforme, has completed, sponsored by NovoCure.

COMPLETED
Registry status
Phase 3
Development phase
236 participants
Enrollment target
20
Study locations

Study Summary

The study is a randomized, controlled trial, designed to test the efficacy and safety of a new medical device, the NovoTTF-100A. The device is an experimental, portable, battery operated device for chronic treatment of patients with recurrent or progressive glioblastoma multiforme (GBM) using alternating electric fields (termed TTFields).

Conditions Studied

Recurrent Glioblastoma Multiforme

Interventions

  • DEVICE NovoTTF-100A

Study Locations (20)

Other

  • University Hospital Graz - Graz
  • FN Brno - Masaryk University - Brno
  • Na Homolce Hospital - Prague
  • Hospital of Neurology Lyon - University Claude Bernard Lyon 1 - Lyon
  • Group Hospitals Pitie-Salpetriere - Paris

Illinois

  • Northwestern University - Chicago
  • University of Illinois in Chicago - Chicago
  • Evanston Northwestern Healthcare - Evanston

Massachusetts

  • Boston University Medical Center - Boston
  • Beth Israel Deaconess Medical Center - Boston
  • Lahey Clinic Medical Center - Burlington

New York

  • Memorial Sloan Kettering Cancer Center - New York
  • Weill Cornell Medical College - New York
  • Columbia University Medical Center - New York

Ohio

  • University Hospitals of Cleveland - Cleveland
  • Cleveland Clinic - Cleveland

New Jersey

  • NJ Neuroscience Institute - JFK Medical Center - Edison

Pennsylvania

  • University of Pittsburgh Medical Center (UPMC) - Pittsburgh

Virginia

  • University of Virginia - Charlottesville

Trial Details

FieldValue
Enrollment Target 236 participants
Start Date 2006-09
Est. Completion 2011-01
Phase Phase 3

Sponsor

NovoCure

11 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00379470

The ClinicalTrials.gov registry entry for NCT00379470 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 236 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 64-participant average among 6 other Recurrent Glioblastoma Multiforme trials with a reported enrollment target (269% higher). The listed sponsor is NovoCure, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Recurrent Glioblastoma Multiforme appearing as the primary indexed condition, and to 1 intervention - of which NovoTTF-100A is the first listed.

NCT00379470 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Illinois, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00379470 about?

NCT00379470 is a clinical study titled "Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)". The study is a randomized, controlled trial, designed to test the efficacy and safety of a new medical device, the NovoTTF-100A. The device is an experimental, portable, battery operated device for chronic treatment of patients with recurrent or progressive glioblastoma multiforme (GBM) using altern...

What is the current status of trial NCT00379470?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 236 participants. The study started on 2006-09. Estimated completion is 2011-01.

What conditions does trial NCT00379470 study?

This clinical trial studies the following conditions: Recurrent Glioblastoma Multiforme.

What interventions are being tested in trial NCT00379470?

The interventions under investigation include: NovoTTF-100A (DEVICE).

Who is sponsoring clinical trial NCT00379470?

This trial is sponsored by NovoCure, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00379470 being conducted?

This trial has 20 study locations across Illinois, Massachusetts, New Jersey, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Glioblastoma Multiforme

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Glioblastoma Multiforme

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.